Heart Failure trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Heart Failure. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month9 studies across 7 companies, in the next 180 days.
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NVO | Novo Nordisk A/S | A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationNCT06200207Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (KCCQ-CSS) | Phase 3 | Active, not recruiting | 2026-10-01 | in 42 d | 2026-07-31 |
November 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| EW | Edwards Lifesciences | ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt SystemNCT05686317Device + Medical Therapy: Subjects with Early Major Adverse Events | Not applicable | Active, not recruiting | 2026-11-01 | in 73 d | 2026-06-04 |
| TECX | Tectonic Therapeutic | A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)NCT06616974Mean change from baseline in Pulmonary Vascular Resistance (PVR) in participants with a combined pre- and post-capillary pulmonary hypertension (CpcPH). | Phase 2 | Active, not recruiting | 2026-11-24 | in 96 d | 2026-07-07 |
December 2026 5
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)NCT06122779Incidence of treatment emergent adverse events (TEAEs) | Phase 2 | Active, not recruiting | 2026-12-14 | in 116 d | 2026-07-30 |
| AZN | AstraZeneca | Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in GermanyNCT06336330observationalTime to discontinuation of dapagliflozin | — | Active, not recruiting | 2026-12-31 | in 133 d | 2026-07-13 |
| BCDA | BioCardia, Inc. | Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem CellsNCT05925608Treatment-emergent serious adverse events | Phase 1/2 | Active, not recruiting | Dec 2026 | ≤ 133 d | 2025-12-12 |
| NVO | Novo Nordisk A/S | A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy ParticipantsNCT07656454Area under the CDR132L plasma concentration-time curve (AUC 0-tz) from 0 hours to tz after a single dose, where tz is the time of last quantifiable concentration | Phase 1 | Recruiting | 2026-12-31 | in 133 d | 2026-06-30 |
| VIS.MC | Viscofan | Safety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem CellsNCT06956807combination of MACCEs at all follow up visits during the first year after treatment | Phase 1 | Not yet recruiting | 2026-12-31 | in 133 d | 2025-05-04 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NVO | Novo Nordisk A/S | A Research Study on the Effects of NNC0537-1482 in Participants With Heart FailureNCT07218627Number of treatment emergent adverse events (TEAE) | Phase 1 | Recruiting | 2027-01-15 | in 148 d | 2026-08-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Heart Failure
most recently updated first293 studies match. Showing the first 100 of 293 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CVRX | CVRx, Inc. | $73M | Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart FailureNCT07232030Primary Effectiveness Endpoint | Not applicable | Recruiting | Device: Barostim System · Other: Usual care medical management | Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III | 2,500 | 2026-04-24 | Jan 2033 | ≤ 2,356 d | 2026-08-19 |
| TENX | Tenax Therapeutics, Inc. | $64M | LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2NCT072883986-Minute Walk Distance (6MWD) | Phase 3 | Recruiting | Drug: TNX-103, Placebo | Pulmonary Hypertension Associated With HFpEF | 540 | 2026-03-03 | 2028-06-30 | in 680 d | 2026-08-19 |
| CYTK | Cytokinetics | $10.6B | Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionNCT06736574Time to the first of event of CV death, HF event, LVAD implantation/cardiac transplantation, or stroke | Phase 3 | Recruiting | Drug: Omecamtiv Mecarbil (OM), Placebo | Heart Failure, Heart Failure With Reduced Ejection Fraction | 1,800 | 2024-12-19 | Sep 2027 | ≤ 406 d | 2026-08-18 |
| NVO | Novo Nordisk A/S | — | A Research Study on the Effects of NNC0537-1482 in Participants With Heart FailureNCT07218627Number of treatment emergent adverse events (TEAE) | Phase 1 | Recruiting | Drug: NNC0537-1482, Placebo | Heart Failure | 36 | 2025-10-23 | 2027-01-15 | in 148 d | 2026-08-18 |
| NVO | Novo Nordisk A/S | — | A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001Time to first occurrence of a composite Heart Failure (HF) endpoint consisting of cardiovascular (CV) death | Phase 3 | Recruiting | Drug: NNC0487-0111, Placebo | Obesity, Heart Failure | 5,610 | 2026-05-11 | 2029-07-23 | in 1,068 d | 2026-08-18 |
| BSX | Boston Scientific Corporation | $73.1B | Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)NCT01385176results2020-01-06Change in Left Ventricular End-systolic Dimension (LVESD) | Not applicable | Active, not recruiting | Device: Implant of investigational device system · Procedure: Titration during the randomization phase, Titration after the randomization phase · Diagnostic test: Blood Draw | Heart Failure, Congestive Heart Failure | 118 | 2011-09-21 | May 2014actual | — | 2026-08-14 |
| NVO | Novo Nordisk A/S | — | A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176Time to First Occurrence of a Composite Heart Failure Endpoint Consisting of: Cardiovascular (CV) Death, Heart Failure (HF) Hospitalisation or Urgent HF Visit | Phase 3 | Active, not recruiting | Drug: Ziltivekimab, Placebo | Heart Failure | 4,899 | 2023-05-08 | 2027-07-02 | in 316 d | 2026-08-12 |
| AZN | AstraZeneca | — | A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117To evaluate the effect of elecoglipron compared with placebo in reducing the risk of CV death or HHF/urgent HF visit | Phase 3 | Not yet recruiting | Drug: Elecoglipron, Placebo | Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF) | 6,950 | 2026-08-28 | 2029-09-03 | in 1,110 d | 2026-08-12 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3971297 in Participants With Heart FailureNCT07547540Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Not yet recruiting | Drug: LY3971297, LY3971297, Placebo, Placebo | Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic | 90 | Aug 2026 | Nov 2027 | ≤ 467 d | 2026-08-10 |
| NVO | Novo Nordisk A/S | — | A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular HypertrophyNCT06979362Main phase: Change in normalised microRNA-132-3p (miR-132) | Phase 2 | Recruiting | Drug: CDR132L, Placebo | Heart Failure | 200 | 2025-06-27 | 2027-11-16 | in 453 d | 2026-08-05 |
| BSX | Boston Scientific Corporation | $73.1B | LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.NCT04790344Heart Failure Event Related Data will be assessed in all subjects through collection of reportable events and subsequent adjudication by the CEC. | Not applicable | Active, not recruiting | Device: Investigational LUX-Dx ICM Implant | Heart Failure | 525 | 2021-03-20 | 2026-07-31actual | — | 2026-08-04 |
| NVO | Novo Nordisk A/S | — | A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationNCT06200207Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (KCCQ-CSS) | Phase 3 | Active, not recruiting | Drug: Ziltivekimab, Placebo | Heart Failure, Systemic Inflammation | 680 | 2024-04-01 | 2026-10-01 | in 42 d | 2026-07-31 |
| AZN | AstraZeneca | — | Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinNCT06677060To determine if baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of an HF event or CV death | Phase 3 | Recruiting | Drug: Baxdrostat and dapagliflozin · Other: Placebo and dapagliflozin | Heart Failure | 11,300 | 2025-03-14 | 2029-12-17 | in 1,215 d | 2026-07-31 |
| CVRX | CVRx, Inc. | $73M | Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)NCT04502316observationalThe primary objective of this post-market registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients that were recently implanted with the Barostim System. | — | Terminatedsponsor's stated reason: Participant follow-up through 12 months post-Barostim Implant sufficient for data collection and analysis purposes. | Device: Barostim™ System | Heart Failure | 435 | 2020-06-26 | 2026-05-14actual | — | 2026-07-30 |
| BMY | Bristol-Myers Squibb | $134.9B | Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)NCT06122779Incidence of treatment emergent adverse events (TEAEs) | Phase 2 | Active, not recruiting | Drug: BMS-986435 · Other: Placebo | Heart Failure | 227 | 2023-11-07 | 2026-12-14 | in 116 d | 2026-07-30 |
| AZN | AstraZeneca | — | iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic DiseasesNCT03549754observational1. Age of particpants | — | Recruiting | — | Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure | 35,000 | 2018-02-17 | 2030-12-31 | in 1,594 d | 2026-07-22 |
| TENX | Tenax Therapeutics, Inc. | $64M | Long-Term Open-Label Extension Study of Oral LevosimendanNCT07436689The incidence (i.e., the percentage of patients who experience at least 1 occurrence) of select AE/SAEs | Phase 3 | Enrolling by invitation | Drug: TNX-103 | Pulmonary Hypertension Associated With HFpEF | 800 | 2026-03-13 | Mar 2029 | ≤ 954 d | 2026-07-20 |
| AZN | AstraZeneca | — | Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in GermanyNCT06675552observationalProportion of patients treated with HFrEF GDMT | — | Recruiting | — | Heart Disease, Heart Failure, Cardiovascular Disease, Heart Failure, Systolic | 438 | 2024-11-15 | 2027-06-30 | in 314 d | 2026-07-14 |
| AZN | AstraZeneca | — | Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in GermanyNCT06336330observationalTime to discontinuation of dapagliflozin | — | Active, not recruiting | — | Heart Diseases, Cardiovascular Diseases, Heart Failure | 831 | 2024-04-25 | 2026-12-31 | in 133 d | 2026-07-13 |
| AZN | AstraZeneca | — | A Phase IIb Study of AZD5462 in Patients With Chronic Heart FailureNCT06299826Cohort A and B: Change from Baseline in Echocardiography Parameters | Phase 2 | Completed | Drug: AZD5462, Placebo | Chronic Heart Failure | 375 | 2024-06-04 | 2026-02-10actual | — | 2026-07-08 |
| TECX | Tectonic Therapeutic | $716M | A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)NCT06616974Mean change from baseline in Pulmonary Vascular Resistance (PVR) in participants with a combined pre- and post-capillary pulmonary hypertension (CpcPH). | Phase 2 | Active, not recruiting | Drug: TX000045- Dose A, TX000045- Dose B, Placebo | Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction | 191 | 2024-09-04 | 2026-11-24 | in 96 d | 2026-07-07 |
| AMGN | Amgen | $229.9B | Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459Time to First Occurrence of a Composite Endpoint Consisting of: CV Death or HF Events | Phase 3 | Recruiting | Drug: Maridebart cafraglutide, Placebo | Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity | 5,056 | 2025-06-25 | 2028-06-30 | in 680 d | 2026-07-02 |
| NVO | Novo Nordisk A/S | — | A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy ParticipantsNCT07656454Area under the CDR132L plasma concentration-time curve (AUC 0-tz) from 0 hours to tz after a single dose, where tz is the time of last quantifiable concentration | Phase 1 | Recruiting | Drug: CDR132L (i.v.), CDR132L (s.c.) | Healthy Volunteers, Heart Failure | 32 | 2026-06-17 | 2026-12-31 | in 133 d | 2026-06-30 |
| NVO | Novo Nordisk A/S | — | A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the SkinNCT06625307Number of treatment emergent adverse events (TEAE) in cohorts 1 and 2 | Phase 1 | Completed | Drug: NNC0537-1482, Placebo | Healthy Volunteers, Heart Failure | 31 | 2024-10-03 | 2025-05-04actual | — | 2026-06-22 |
| EW | Edwards Lifesciences | $52.4B | ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt SystemNCT05686317Device + Medical Therapy: Subjects with Early Major Adverse Events | Not applicable | Active, not recruiting | Device: Edwards APTURE transcatheter shunt system · Diagnostic test: Sham procedure | Heart Failure | 100 | 2023-04-01 | 2026-11-01 | in 73 d | 2026-06-04 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)NCT06991257Number of Participants with Clinical Events | Phase 2 | Recruiting | Drug: Placebo, Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948 | Heart Failure | 620 | 2025-06-19 | 2027-11-16 | in 453 d | 2026-05-27 |
| MDT | Medtronic | $117.9B | Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy ProductsNCT00271180observationalLead related complications for each lead model. | — | Recruiting | Device | Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia | 20,000 | Jan 1983 | Dec 2040 | ≤ 5,247 d | 2026-05-07 |
| EW | Edwards Lifesciences | $52.4B | ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)NCT01757665results2019-12-27Subjects With Structural Valve Deterioration | Not applicable | Completed | Device: Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M | Aortic Stenosis, Mitral Stenosis, Aortic Valve Insufficiency, Mitral Valve Insufficiency, Heart Failure | 777 | 2012-12-11 | Aug 2017actual | — | 2026-05-07 |
| TENX | Tenax Therapeutics, Inc. | $64M | Open-Label Rollover Study of Levosimendan in PH-HFpEF PatientsNCT03624010results2026-04-22Clinical Safety | Phase 2 | Completed | Drug: Levosimendan | Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction | 35 | 2019-04-09 | 2023-04-25actual | — | 2026-04-22 |
| AZN | AstraZeneca | — | A Study to Assess Multidomain Endpoints of an ECG PatchNCT06243029observationalChange in patch-measured variables between baseline and follow-up at 6-8 weeks (multiple variables) using the ECG patch. | — | Completed | Device: ECG Patch | Acute Decompensated Heart Failure | 54 | 2024-01-08 | 2026-03-13actual | — | 2026-03-25 |
| MESO | Mesoblast, Inc. | — | Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart FailureNCT02032004results2026-03-23Time to Recurrent Non-fatal Decompensated Heart Failure Major Adverse Cardiac Events (HF-MACE) That Occur Prior to the First Terminal Cardiac Event (TCE) | Phase 3 | Completed | Biological: Rexlemestrocel-L · Other: Sham Comparator | Chronic Heart Failure | 565 | 2014-03-03 | 2020-01-30actual | — | 2026-03-23 |
| PFE | Pfizer | $155.3B | A Study of Ponsegromab in People With Heart FailureNCT05492500results2026-03-18Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ)-23 - Clinical Summary Score (CSS) at Week 22: Cohort A, Ponsegromab 300 mg Versus Placebo | Phase 2 | Terminatedsponsor's stated reason: Following a prespecified interim analysis, and in consultation with the independent Data Monitoring Committee, the Sponsor terminated the study | Drug: Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort D: Ponsegromab high dose · Other: Main cohort (Cohort A): Matched placebo, Optional Cohort C: Matched placebo, Optional Cohort D: Matched placebo | Heart Failure | 455 | 2022-09-26 | 2025-03-05actual | — | 2026-03-18 |
| NVO | Novo Nordisk A/S | — | A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular HypertrophyNCT06979375Main Phase: Change in normalised microRNA-132-3p (miR-132) | Phase 2 | Recruiting | Drug: CDR132L, Placebo | Heart Failure | 200 | 2025-06-30 | 2027-05-16 | in 269 d | 2026-03-11 |
| CVRX | CVRx, Inc. | $73M | Baroreflex Activation Therapy for Heart FailureNCT02627196results2026-03-10Rate of Cardiovascular Mortality and Heart Failure Morbidity | Not applicable | Completed | Device: BAROSTIM NEO® System · Drug: Medical Management | Heart Failure | 1,090 | 2016-04-19 | Oct 2023actual | — | 2026-03-10 |
| EW | Edwards Lifesciences | $52.4B | TRISCEND II Pivotal TrialNCT04482062Randomized Cohort: Tricuspid Regurgitation (TR) grade reduction | Not applicable | Active, not recruiting | Device: Edwards EVOQUE System · Drug: Optimal Medical Therapy | Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure | 864 | 2021-04-09 | 2025-12-05actual | — | 2026-02-27 |
| NVO | Novo Nordisk A/S | — | Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure ManagementNCT07160829observationalPerceptions towards role of systemic inflammation in identification, treatment, management of ASCVD+CKD and HF | — | Completed | Other: No treatment given | Atherosclerotic Cardiovascular Disease, Heart Failure, Chronic Kidney Disease | 608 | 2025-09-18 | 2025-10-30actual | — | 2026-02-11 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)NCT05592275results2026-02-05Change From Baseline in Left Atrial Reservoir Strain (LARS) at Week 26 | Phase 2 | Terminatedsponsor's stated reason: An interim was conducted and after review of available data, including efficacy evaluation of heart failure events, Lilly is terminating the study due to low likelihood of study success for this HFpEF patient population. | Drug: LY3540378, Placebo | Heart Failure, Heart Failure With Preserved Ejection Fraction | 332 | 2023-02-03 | 2025-01-22actual | — | 2026-02-05 |
| MDT | Medtronic | $117.9B | Personalized Therapy Study - Attain Stability Quad Post-Approval StudyNCT04024943observationalPercentage of patients without a lead- related event at 5 years post-implant | — | Active, not recruiting | Device: Quadripolar LV Lead | Heart Failure | 1,092 | 2017-08-21 | Jul 2027 | ≤ 345 d | 2026-02-04 |
| EW | Edwards Lifesciences | $52.4B | Exploratory Study of the Edwards APTURE Transcatheter Shunt System (ALT-FLOW Canada)NCT04000607Rate of major cardiac/cerebrovascular/renal events and re-intervention (Safety Endpoint) | Not applicable | Active, not recruiting | Device: APTURE transcatheter shunt | Heart Failure | 45 | 2019-07-10 | 2023-11-03actual | — | 2026-01-27 |
| NVO | Novo Nordisk A/S | — | A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real WorldNCT07141914observationalRevised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event) | — | Completed | Other: No treatment given, No treatment given | Overweight, Obesity, Heart Failure (HF), Atherosclerotic Cardiovascular Disease (ASCVD), Primary Prevention | 285,327 | 2025-08-29 | 2025-12-19actual | — | 2026-01-23 |
| REGN | Regeneron Pharmaceuticals | $76.1B | REGN5381 in Adult Participants With Heart Failure With Reduced Ejection FractionNCT06237309Change from baseline in circulating N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: REGN5381, Placebo | Heart Failure | 89 | 2024-04-11 | 2025-09-17actual | — | 2026-01-14 |
| BCDA | BioCardia, Inc. | $225M | Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem CellsNCT05925608Treatment-emergent serious adverse events | Phase 1/2 | Active, not recruiting | Combination product: CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) · Diagnostic test: Diagnostic Catheterization | Heart Failure, Systolic | 39 | 2023-08-23 | Dec 2026 | ≤ 133 d | 2025-12-12 |
| AZN | AstraZeneca | — | Real-world Dapagliflozin Experience in Patients With Heart Failure in GreeceNCT05635331observationalBaseline characteristics (demographic and clinical) | — | Completed | — | Heart Failure | 257 | 2022-12-28 | 2024-12-03actual | — | 2025-11-24 |
| EW | Edwards Lifesciences | $52.4B | PARTNER 3 Trial - Mitral Valve in ValveNCT03193801results2023-10-24Safety and Effectiveness - Composite of All-cause Mortality and Stroke | Not applicable | Active, not recruiting | Device: Edwards SAPIEN 3 transcatheter valve, Model 9600TFX | Mitral Valve Insufficiency, Mitral Valve Disease, Mitral Valve Regurgitation, Heart Failure | 53 | 2018-02-01 | 2022-08-16actual | — | 2025-11-05 |
| MDT | Medtronic | $117.9B | Personalized Therapy Study - HFRS (TriageHF) Post Approval StudyNCT04489225observationalpositive predictive value (PPV) of HFRS High Risk Status associated with worsening heart failure | — | Active, not recruiting | Other: Observational | Heart Failure | 2,200 | 2020-08-01 | 2024-12-06actual | — | 2025-10-20 |
| AZN | AstraZeneca | — | A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2NCT05737940Change from baseline in Pulmonary Vascular Resistance (PVR) | Phase 2 | Completed | Drug: AZD3427, Placebo | Pulmonary Hypertension (World Health Organization Group 2), Heart Failure | 260 | 2023-04-24 | 2025-07-15actual | — | 2025-09-24 |
| AZN | AstraZeneca | — | AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal ImpairmentNCT06611423The volumetric fraction (%) of the renal cortex with increased perfusion from baseline to Day 8, compared to placebo. | Phase 1 | Terminatedsponsor's stated reason: The Sponsor encountered difficulties in recruiting patients for clinical trial D8330C00004 and decided to end the study earlier for business reasons not affecting the benefit-risk balance. | Biological: AZD3427 · Other: AZD3427 Placebo, Radiolabelled ligand, Saline · Drug: Dopamine | Heart Failure With Reduced Ejection Fraction (HFrEF), Renal Impairment | 10 | 2024-10-15 | 2025-08-21actual | — | 2025-09-24 |
| AZN | AstraZeneca | — | A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal ImpairmentNCT06639087Change in sodium excretion | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: AZD5462, Dapagliflozin · Other: Placebo | Renal Impairment, Heart Failure | 8 | 2024-09-27 | 2025-05-29actual | — | 2025-09-24 |
| BCDA | BioCardia, Inc. | $225M | CardiAMP™ Cell Therapy for Heart Failure TrialNCT02438306A composite endpoint based on a 3-tiered Finkelstein-Schoenfeld (FS) hierarchical analysis. | Phase 3 | Completed | Biological: Autologous cell therapy · Other: Sham | Heart Failure, Systolic | 125 | Dec 2016 | Feb 2025actual | — | 2025-09-19 |
| EW | Edwards Lifesciences | $52.4B | Early Feasibility Study - Edwards APTURE Transcatheter Shunt SystemNCT03523416Rate of major cardiac/cerebrovascular/renal events and re-intervention (Safety Endpoint) | Not applicable | Active, not recruiting | Device: Transcatheter Atrial Shunt System | Heart Failure | 71 | 2018-07-31 | 2023-12-15actual | — | 2025-09-19 |
| AZN | AstraZeneca | — | Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%NCT04986202results2025-08-27Kansas City Cardiomyopathy Questionnaire -Total Symptom Score | Phase 2/3 | Completed | Drug: AZD4831 · Other: Placebo | Heart Failure With Preserved Ejection Fraction | 711 | 2021-06-30 | 2024-03-27actual | — | 2025-08-27 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialNCT04847557results2025-08-20Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) | Phase 3 | Completed | Drug: Tirzepatide · Other: Placebo | Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF) | 731 | 2021-04-20 | 2024-07-02actual | — | 2025-08-20 |
| AZN | AstraZeneca | — | Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving SpironolactoneNCT04676646results2025-07-09Participants Who Achieved Response, Defined as Serum Potassium (sK+) Within 3.5 to 5.0 mEq/L, Spironolactone Greater Than or Equal to 25 mg Daily, no Rescue Therapy for Hyperkalaemia | Phase 4 | Completed | Drug: Sodium zirconium cyclosilicate, Placebo · Other: Spironolactone | Hyperkalaemia, Heart Failure With Reduced Ejection Fraction | 366 | 2021-03-08 | 2024-07-15actual | — | 2025-07-09 |
| AZN | AstraZeneca | — | A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462NCT06989983Amount of AZD5462 excreted (Ae) - Period 1 | Phase 1 | Completed | Drug: AZD5462 film-coated tablet, [14C]AZD5462 Solution for Infusion, [14C]AZD5462 Oral Solution | Heart Failure | 8 | 2025-05-20 | 2025-06-25actual | — | 2025-07-04 |
| AZN | AstraZeneca | — | Forxiga HF General Drug Use-Results StudyNCT04865406observationalfrequency of adverse drug reactions (ADRs) | — | Completed | — | Heart Failure | 1,221 | 2021-05-10 | 2024-08-22actual | — | 2025-07-03 |
| REGN | Regeneron Pharmaceuticals | $76.1B | REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge PressureNCT05353166Incidence and severity of treatment-emergent adverse events (TEAEs) | Phase 2 | Completed | Drug: REGN5381, Matching Placebo | Heart Failure | 59 | 2022-06-30 | 2025-06-02actual | — | 2025-06-11 |
| AZN | AstraZeneca | — | Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)NCT05465213observationalTime to dapagliflozin treatment discontinuation | — | Completed | — | Heart Failure | 283 | 2022-11-28 | 2024-06-24actual | — | 2025-06-06 |
| AZN | AstraZeneca | — | Heart Failure Patients RegistryNCT04709263observationalMean age | — | Completed | — | Heart Failure | 19,990 | 2020-12-21 | 2024-03-28actual | — | 2025-05-15 |
| EW | Edwards Lifesciences | $52.4B | Magna® Mitral Pericardial Bioprostheses Post-Approval Study ProtocolNCT00853632results2025-05-14Subject's Rate of Objective Performance Criteria Per ISO 5840-2005 - Total Number of Late Adverse Events (by Category) Divided by Late Patient Years (Expressed as a Percentage) for the Magna Mitral Valve Implanted Cohort | Not applicable | Completed | Device: CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES | Coronary Artery Disease, Mitral Valve Regurgitation, Mitral Valve Incompetence, Heart Failure | 329 | Aug 2007 | 2024-03-06actual | — | 2025-05-14 |
| NVO | Novo Nordisk A/S | — | Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)NCT06122961observationalHigh sensitivity C-reactive protein (hsCRP) greater than or equal to 2 mg/L (yes/ no) | — | Completed | Other: No treatment given | Cardiovascular Risk, Heart Failure, Chronic Kidney Disease | 18,198 | 2023-11-23 | 2025-04-30actual | — | 2025-05-09 |
| VIS.MC | Viscofan | $3.0B | Safety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem CellsNCT06956807combination of MACCEs at all follow up visits during the first year after treatment | Phase 1 | Not yet recruiting | Combination product: VB-C01 cellularised patch | CABG-patients, Heart Failure, Myocardial Infarction (MI) | 10 | 2025-09-01 | 2026-12-31 | in 133 d | 2025-05-04 |
| CVRX | CVRx, Inc. | $73M | Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical EvidenceNCT05860348observationalChange in Six Minute Hall Walk | — | Terminatedsponsor's stated reason: Lack of enrollment | Device: Barostim™ System | Heart Failure | 5 | 2023-07-25 | 2024-09-04actual | — | 2025-04-08 |
| CVRX | CVRx, Inc. | $73M | BATwire Implant KitNCT04600791Freedom from Serious Adverse Events (SAEs) related to the implantation of the lead using the BATwire Implant Kit through 30 days post implant | Not applicable | Terminatedsponsor's stated reason: 1\. Slow enrollment and enough experience gained from the first in human phase of the study and would like to evaluate the findings. | Device: BATwire Implant Kit | Heart Failure | 93 | 2021-01-29 | 2024-08-28actual | — | 2025-03-30 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnTNCT04766892results2025-03-20Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Phase 2 | Completed | Drug: mavacamten | Heart Failure With Preserved Ejection Fraction | 30 | 2021-03-30 | 2024-02-26actual | — | 2025-03-20 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart FailureNCT05659264Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Phase 1 | Completed | Drug: mRNA-0184, Placebo | Chronic Heart Failure | 48 | 2022-12-05 | 2024-12-17actual | — | 2025-03-17 |
| AZN | AstraZeneca | — | Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.NCT04564742results2025-03-07Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Phase 3 | Completed | Drug: Dapagliflozin, Placebo | Acute Myocardial Infarction, Heart Failure | 4,017 | 2020-12-22 | 2023-07-05actual | — | 2025-03-07 |
| AZN | AstraZeneca | — | Real-world Dapagliflozin Experience in Patients With Heart Failure in United Kingdom.NCT05188144observationalTime to dapagliflozin treatment discontinuation | — | Completed | — | Heart Failure | 237 | 2021-11-29 | 2024-03-02actual | — | 2025-02-25 |
| AZN | AstraZeneca | — | Dapagliflozin Post Marketing Surveillance in HF and CKDNCT05134701observationalIncidence (%) of adverse events (AEs), serious AEs (SAEs), adverse drug reactions (ADRs), serious ADRs (SADRs), unexpected AEs/ADRs, unexpected SAEs, SADRs | — | Completed | — | Heart Failure, Chronic Kidney Disease | 815 | 2022-03-10 | 2024-05-20actual | — | 2025-01-13 |
| TENX | Tenax Therapeutics, Inc. | $64M | Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEFNCT03541603results2024-05-14Change From Baseline Pulmonary Capillary Wedge Pressure (PCWP) With Bicycle Exercise | Phase 2 | Completed | Drug: Levosimendan, Matching Placebo | Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction | 44 | 2018-11-14 | 2020-04-07actual | — | 2024-11-20 |
| AZN | AstraZeneca | — | Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney DiseaseNCT04595370results2024-11-19Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 | Phase 2 | Completed | Drug: AZD9977, Dapagliflozin | Heart Failure, Chronic Kidney Disease | 153 | 2021-01-26 | 2023-09-22actual | — | 2024-11-19 |
| NVS | Novartis | — | Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection FractionNCT06671314observationalTime Spent 30 Days Post-discharge by Discharge Sacubitril/Valsartan (SAC/VAL) Prescription Status | — | Completed | — | Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction | 42,494 | 2022-06-02 | 2022-10-31actual | — | 2024-11-04 |
| AZN | AstraZeneca | — | AZD8601 Study in CABG PatientsNCT03370887results2024-10-10Number of Subjects With Adverse Events | Phase 2 | Completed | Drug: AZD8601, Placebo | Heart Failure | 11 | 2018-02-05 | 2021-06-30actual | — | 2024-10-10 |
| EW | Edwards Lifesciences | $52.4B | ExplorATory Study oF the EdWards Transcatheter Atrial Shunt System (AlT FloW Germany)NCT04965623Rate of Safety Events (MACCREE, Re-Intervention) | Not applicable | Withdrawnsponsor's stated reason: This study was not initiated due to Covid. Then, Edwards Lifesciences elected to withdraw this study due to the initiation of the ALT-FLOW II randomized trial in Germany. | Device: Atrial Shunt | Heart Failure | 0 | 2021-02-22 | 2023-12-06actual | — | 2024-09-19 |
| AZN | AstraZeneca | — | PORTHOS - PORTuguese Heart Failure Observational StudyNCT05434923observationalPrevalence of HF among the mainland resident Portuguese population aged 50 or above. | — | Completed | — | Heart Failure | 6,189 | 2022-06-30 | 2023-09-18actual | — | 2024-08-26 |
| PFE | Pfizer | $155.3B | Global Prevalence of ATTR-CM in Participants With HFpEFNCT04424914results2024-07-19Global Prevalence of ATTR-CM in HFpEF Participants Clinically At-Risk of Disease Among Total Evaluable Participants | Not applicable | Terminatedsponsor's stated reason: Sponsor terminated study early to not prolong timelines and to enable sharing of data collected which has potential to better support understanding of the prevalence of ATTR-CM in patients with HFpEF. Decision was not based on any safety findings. | Diagnostic test: Scintigraphy | Transthyretin Amyloid Cardiomyopathy, Heart Failure With Preserved Ejection Fraction | 347 | 2020-12-30 | 2023-06-02actual | — | 2024-07-19 |
| PFE | Pfizer | $155.3B | Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride CapsulesNCT04967443results2024-07-12Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Prazosin | Phase 1 | Completed | Drug: Prazosin HCl 2mg, Prazosin HCl 1 mg, Prazosin HCl 5 mg | Hypertension, Heart Failure | 72 | 2021-09-22 | 2022-02-15actual | — | 2024-07-12 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection FractionNCT04840914Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Completed | Drug: LY3461767, Placebo | Chronic Heart Failure With Reduced Ejection Fraction | 44 | 2021-06-01 | 2024-05-09actual | — | 2024-05-30 |
| OGN | Organon and Co | $3.6B | Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)NCT00090259results2010-08-02Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure | Phase 3 | Completed | Drug: Losartan 50 mg, Losartan 150 mg | Heart Failure | 3,834 | 2001-12-19 | 2009-03-31actual | — | 2024-05-16 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart FailureNCT05952089Maximum observed plasma concentration (Cmax) | Phase 1 | Completed | Drug: Danicamtiv, Midazolam | Heart Failure With Reduced Ejection Fraction | 13 | 2023-08-17 | 2024-03-15actual | — | 2024-04-04 |
| BSX | Boston Scientific Corporation | $73.1B | Multiple Cardiac Sensors for the Management of Heart FailureNCT03237858results2024-03-27Manage-HF Phase I | Not applicable | Completed | Device: HeartLogic ON, HeartLogic OFF | Heart Failure, Congestive | 200 | 2017-08-30 | 2020-07-21actual | — | 2024-03-27 |
| BSX | Boston Scientific Corporation | $73.1B | Ingenio Device Algorithm StudyNCT01441583results2024-03-21Accuracy of Commanded Right Atrial Automatic Threshold (RAAT) | Not applicable | Completed | Device: RAAT, RYTHMIQ | Sinus Node Disease, AV Block, Heart Failure | 139 | Oct 2011 | Jun 2012actual | — | 2024-03-21 |
| BFLY | Butterfly Network | $2.2B | Heart Failure Monitoring With a Portable Ultrasound Device With Artificial Intelligence Assisted Tools: A Multi-Phase Observational Feasibility StudyNCT05594940observationalPatients Image Quality | — | Terminatedsponsor's stated reason: Data Analysis | — | Congestive Heart Failure | 22 | 2022-09-21 | 2024-02-23actual | — | 2024-02-26 |
| VTRS | Viatris Inc. | $18.6B | A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting ConditionsNCT06266988Bioequivalence based on Cmax period (using the validated Phoenix® WinNonlin® software) | Phase 1 | Unknown status | Drug: Sacubitril and Valsartan Tablets 97mg/103mg, Entresto (Sacubitril and Valsartan Tablets 97mg/103mg) | Chronic Heart Failure | 48 | Mar 2024 | Apr 2024 | — | 2024-02-20 |
| INGN | Inogen Inc. | $149M | Portable Oxygen Concentrator in Non-hospitalized Patients With Chronic Heart FailureNCT05719363Walking distance during the 6MWT | Not applicable | Completed | Device: Inogen Rove 6 Portable Oxygen Concentrator | Heart Failure | 20 | 2023-10-11 | 2023-11-21actual | — | 2024-01-03 |
| BSX | Boston Scientific Corporation | $73.1B | Step and Walking Pattern From Cardiac Monitor StudyNCT04971993observationalStep Detection | — | Terminatedsponsor's stated reason: Resourcing challenges | Device: Wearable Cardiac Monitor | Heart Failure NYHA Class II, Heart Failure NYHA Class III, Insertable Cardiac Monitor | 40 | 2022-01-05 | 2023-10-11actual | — | 2023-12-13 |
| BSX | Boston Scientific Corporation | $73.1B | Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy RegistryNCT03075215results2023-10-02observationalCRT Response Rate | — | Completed | Device: Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D) | Heart Failure | 2,044 | 2017-04-14 | 2021-11-15actual | — | 2023-10-25 |
| NVS | Novartis | — | The VALIDATE Study of Valsartan for Patients With Early Stage Heart FailureNCT00241098Change from baseline in a blood measurement for heart failure after 26 weeks | Phase 4 | Completed | Drug: valsartan | Hypertension, Congestive Heart Failure | 37 | May 2003 | Jun 2005actual | — | 2023-10-18 |
| LIVN | LivaNova | $4.4B | ANTHEM-HFrEF Pivotal StudyNCT03425422Event-free rate | Not applicable | Terminatedsponsor's stated reason: Company decision to stop enrolling not associated with any safety concerns. | Device: VITARIA System | Heart Failure, Heart Failure, Congestive, Heart Failure, Systolic | 533 | 2018-05-01 | 2023-05-31actual | — | 2023-10-10 |
| BIIB | Biogen | $31.4B | Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal InsufficiencyNCT00709865Assess the safety andtolerability of intravenous tonapofylline, when added to standard therapy in subjects hospitalized with ADHF and renal insufficiency. | Phase 3 | Completed | Drug: tonapofylline, Placebo | Renal Insufficiency, Congestive Heart Failure | 420 | 2008-07-31 | 2009-10-30actual | — | 2023-09-11 |
| BIIB | Biogen | $31.4B | Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal InsufficiencyNCT00745316To assess the safety and tolerability of BG9928 administered to subjects with heart failure and renal insufficiency. | Phase 2 | Terminatedsponsor's stated reason: Company Decision | Drug: Tonapofylline, Placebo | Renal Insufficiency, Heart Failure | 34 | Feb 2009 | Jan 2010actual | — | 2023-09-11 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection FractionNCT04836182Percent Change in Plasma AGT Concentration From Baseline to Study Day 85 | Phase 2 | Completed | Drug: IONIS-AGT-LRx, Placebo | Chronic Heart Failure With Reduced Ejection Fraction | 72 | 2021-06-08 | 2022-10-19actual | — | 2023-09-11 |
| AMGN | Amgen | $229.9B | Heart Failure Study to Evaluate Vital Signs and Overcome Low Use of Guideline-Directed Therapy by Remote MonitoringNCT04292275Time to Change or Decision That Heart Failure Therapy is Optimal | Not applicable | Terminatedsponsor's stated reason: Study closed prematurely due to enrollment challenges exacerbated by COVID-19. | Device: Biobeat Wrist Watch · Other: Standard of Care | Heart Failure | 18 | 2020-03-06 | 2021-10-01actual | — | 2023-08-08 |
| SEQUA.BR | Sequana Medical N.V. | $19M | Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0NCT05965934Adverse event rate through end of treatment period | Phase 1/2 | Unknown status | Drug: Direct Sodium Removal Infusate 2.0 | Heart Failure, Volume Overload | 33 | 2023-07-07 | 2024-12-31 | — | 2023-07-28 |
| ELUT | Elutia Inc. | $42M | Retrospective Experience Of CIED ImplantationNCT04351269results2022-05-18observationalNumber of Participants With Major Infection Post Procedure | — | Completed | Device: CanGaroo Envelope, TYRX Envelope | Cardiac Disease, Heart Failure, Coronary Artery Disease | 597 | 2020-04-22 | 2021-06-30actual | — | 2023-07-21 |
| AZN | AstraZeneca | — | Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.NCT03619213results2023-07-11Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. | Phase 3 | Completed | Drug: Dapagliflozin, Placebo | Heart Failure With Preserved Ejection Fraction | 6,263 | 2018-08-27 | 2022-03-27actual | — | 2023-07-11 |
| AZN | AstraZeneca | — | Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium LevelsNCT05184998observationalthe percentages of patients experiencing a composite of rehospitalization for worsened HF and CV death | — | Completed | — | Hyperkalemia, Hypokalemia, Heart Failure | 6,950 | 2021-11-30 | 2022-07-13actual | — | 2023-07-10 |
| AZN | AstraZeneca | — | Study of Verinurad in Heart Failure With Preserved Ejection FractionNCT04327024results2023-06-29Change From Baseline at Week 32 in Peak V02 Consumption in Verinurad + Allopurinol Compared to Placebo (ANCOVA Model) | Phase 2 | Completed | Drug: Verinurad, Allopurinol, Placebo for verinurad, Placebo for allopurinol | Heart Failure With Preserved Ejection Fraction (HFpEF) | 159 | 2020-05-19 | 2022-04-29actual | — | 2023-06-29 |
| WINT | Windtree Therapeutics | $37,080 | The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart FailureNCT02617446results2023-05-24Change in E/Ea Ratio | Phase 2 | Completed | Drug: Placebo, Istaroxime | Acute Decompensated Heart Failure | 120 | Dec 2015 | 2018-08-14actual | — | 2023-05-24 |
| CVRX | CVRx, Inc. | $73M | BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection FractionNCT02876042observationalChanges in Office Cuff Systolic Blood Pressure | — | Unknown status | Device: BAROSTIM NEO™ System | Heart Failure | 70 | 2017-03-23 | Jul 2024 | — | 2023-04-20 |
| CVRX | CVRx, Inc. | $73M | BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection FractionNCT02880618observationalChange in New York Heart Association Functional Classification at 6 months Post-Implant | — | Unknown status | Device: Barostim Neo™ System | Heart Failure | 500 | 2016-12-13 | Jul 2024 | — | 2023-04-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Heart Failure is matched — 20 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Heart Failure
- Congestive Heart Failure
- Heart Failure, Congestive
- Chronic Heart Failure
- Heart Failure With Preserved Ejection Fraction
- Heart Failure With Reduced Ejection Fraction
- Heart Failure, Systolic
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Acute Decompensated Heart Failure
- Cardiac Failure
- Heart Failure (HF)
- Diastolic Heart Failure
- Chronic Heart Failure With Reduced Ejection Fraction
- Heart Failure With Normal Ejection Fraction
- Pulmonary Hypertension Associated With HFpEF
- Acute Heart Failure
- Heart Failure NYHA Class II
- Heart Failure NYHA Class III
- Heart Failure With Reduced Ejection Fraction (HFrEF)
- Heart Failure, Diastolic
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Heart Failure” (a text search, wider than this page)